Maverex is presenting 7 posters at ISPOR Europe 2025

The Maverex team is pleased to share that we will be presenting 7 posters at ISPOR Europe 2025 in Glasgow, highlighting our latest research across health technology assessment (HTA), environmental sustainability, health equality, and innovation in healthcare:

Caregiver Quality of Life in Orphan Drug Health Technology Assessment Submissions in Europe: A Comparative Analysis

Poster session 1; 10:30–13:30; 10th November; Poster code: HTA65

Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease, Hypertension and Diabetes

Poster session 2; 16:00–19:00; 10th November; Poster code: HPR61

Use of AI in Breast Cancer Screening in England Has a Minimal Impact on Greenhouse Gas Emissions and May Increase Diagnostic Accuracy

Poster session 5; 09:00–11:30; 12th November; Poster code: MT45

Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting from the Treatment of Obese Individuals with Type 2 Diabetes

Poster session 1; 10:30–13:30; 10th November; Poster code: HSD8

Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023–2025

Poster session 1; 10:30–13:30; 10th November; Poster code: HTA24

Are Women’s Health Strategies Driving Change? A Review of NICE and SMC HTAs ​

Poster session 4; 16:00–19:30; 11th November; Poster code: HTA41

Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies

Poster session 5; 09:00–11:30; 12th November; Poster code: HTA373

Previous
Previous

Microtutorials from Maverex at ISPOR Europe 2025

Next
Next

Maverex at the World Orphan Drug Congress 2025